Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/125927
Title: Overlapping demyelinating syndromes and anti-NMDA receptor encephalitis
Author: Titulaer, Maarten J.
Höftberger, Romana
Iizuka, Takahiro
Leypoldt, Frank
McCracken, Lindsey
Cellucci, Tania
Benson, Leslie A.
Shu, Huidy
Irioka, Takashi
Hirano, Makito
Singh, Gagandeep
Cobo Calvo, Álvaro
Kaida, Kenichi
Morales, Pamela S.
Wirtz, Paul W.
Yamamoto, Tomotaka
Reindl, Markus
Rosenfeld, Myrna R.
Graus Ribas, Francesc
Saiz Hinajeros, Albert
Dalmau Obrador, Josep
Keywords: Encefalitis
Receptors cel·lulars
Encephalitis
Cell receptors
Issue Date: 11-Feb-2014
Publisher: Wiley-Liss
Abstract: Objective: To report the clinical, radiological, and immunological association of demyelinating disorders with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Methods: Clinical and radiological analysis was done of a cohort of 691 patients with anti-NMDAR encephalitis. Determination of antibodies to NMDAR, aquaporin-4 (AQP4), and myelin oligodendrocyte glycoprotein (MOG) was performed using brain immunohistochemistry and cell-based assays. Results: Twenty-three of 691 patients with anti-NMDAR encephalitis had prominent magnetic resonance imaging (MRI) and/or clinical features of demyelination. Group 1 included 12 patients in whom anti-NMDAR encephalitis was preceded or followed by independent episodes of neuromyelitis optica (NMO) spectrum disorder (5 cases, 4 anti-AQP4 positive) or brainstem or multifocal demyelinating syndromes (7 cases, all anti-MOG positive). Group 2 included 11 patients in whom anti-NMDAR encephalitis occurred simultaneously with MRI and symptoms compatible with demyelination (5 AQ4 positive, 2 MOG positive). Group 3 (136 controls) included 50 randomly selected patients with typical anti-NMDAR encephalitis, 56 with NMO, and 30 with multiple sclerosis; NMDAR antibodies were detected only in the 50 anti-NMDAR patients, MOG antibodies in 3 of 50 anti-NMDAR and 1 of 56 NMO patients, and AQP4 antibodies in 48 of 56 NMO and 1 of 50 anti-NMDAR patients (p < 0.0001 for all comparisons with Groups 1 and 2). Most patients improved with immunotherapy, but compared with anti-NMDAR encephalitis the demyelinating episodes required more intensive therapy and resulted in more residual deficits. Only 1 of 23 NMDAR patients with signs of demyelination had ovarian teratoma compared with 18 of 50 anti-NMDAR controls (p = 0.011). Interpretation: Patients with anti-NMDAR encephalitis may develop concurrent or separate episodes of demyelinating disorders, and conversely patients with NMO or demyelinating disorders with atypical symptoms (eg, dyskinesias, psychosis) may have anti-NMDAR encephalitis.
Note: Versió postprint del document publicat a: https://doi.org/10.1002/ana.24117
It is part of: Annals of Neurology, 2014, vol. 75, num. 3, p. 411-428
URI: http://hdl.handle.net/2445/125927
Related resource: https://doi.org/10.1002/ana.24117
ISSN: 0364-5134
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
654289.pdf993.16 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.